M
Mabgeek Biotechnology
Maiji Biopharma, the first domestic company to list, leads globally in independent R&D and clinical trials of innovative antibodies
About Mabgeek Biotechnology
Hunan Mabgeek Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company established in 2016 by founder Dr. Zhang Chenghai. The firm concentrates on the independent research, development, and commercialization of antibody drugs to address unmet clinical needs in allergic inflammatory and autoimmune diseases. Dr. Zhang Chenghai has a background in overseeing the research and clinical application of numerous antibody drugs, bringing extensive experience to the company's focus. Mabgeek Biotechnology operates in the drug discovery industry, specifically targeting the immuno-inflammation field.
The company's business model is centered on the development and subsequent commercialization of a pipeline of innovative antibody drugs. A key asset is the proprietary TEADA antibody discovery platform, which is designed to efficiently screen for candidate molecules with high biological activity and favorable drug-like properties. Mabgeek has entered into strategic collaborations to advance its pipeline, such as a partnership with Chime Biologics for manufacturing and development, and another with China Medical System for co-development and commercialization rights of its lead product in several Asian territories. In August 2025, the company filed for an Initial Public Offering (IPO) in Hong Kong to secure funding for its development pipeline.
Mabgeek's primary product candidate is MG-K10, a long-acting monoclonal antibody that targets the IL-4Rα receptor. This antibody is designed to simultaneously block two key cytokines, IL-4 and IL-13, which are involved in type 2 inflammatory diseases. A significant feature of MG-K10 is its extended half-life, allowing for a less frequent dosing schedule of once every four weeks, compared to the current standard of every two weeks for similar treatments. The drug is currently in Phase III clinical trials for moderate-to-severe atopic dermatitis and asthma. The company's pipeline also includes other antibody candidates in various stages of development, such as anti-TSLP (Phase I), anti-IL-33, and anti-MASP-2 mAb, for conditions in dermatology, respiratory, and nephrology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Research and Development, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jul 2025 | $14M | $363M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Aug 2024 | $28M | $138M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Mabgeek Biotechnology is 2.2K monthly website visits, up 22.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mabgeek Biotechnology in its local ecosystem
The Mabgeek Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mabgeek Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mabgeek Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








